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Abstract
Objectives: Injection drug users (IDUs) are at high risk for HIV, hepatitis, overdose and other harms. Greater drug
treatment availability has been shown to reduce these harms among IDUs. Yet, little is known about changes in
drug treatment availability for IDUs in the U.S. This paper investigates change in drug treatment coverage for IDUs
in 90 metropolitan statistical areas (MSAs) during 1993-2002.
Methods: We define treatment coverage as the percent of IDUs who are in treatment. The number of IDUs in drug
treatment is calculated from treatment entry data and treatment census data acquired from the Substance Abuse
and Mental Health Service Administration, divided by our estimated number of IDUs in each MSA.
Results: Treatment coverage was low in 1993 (mean 6.7%; median 6.0%) and only increased to a mean of 8.3%
and median of 8.0% coverage in 2002.
Conclusions: Although some MSAs experienced increases in treatment coverage over time, overall levels of
coverage were low. The persistence of low drug treatment coverage for IDUs represents a failure by the U.S. health
care system to prevent avoidable harms and unnecessary deaths in this population. Policy makers should expand
drug treatment for IDUs to reduce blood-borne infections and community harms associated with untreated
injection drug use.
Introduction
The HIV/AIDS epidemic among injection drug users
(IDUs) is a critically important public health issue in the
United States (U.S.). Currently, IDUs are the third high-
est risk group for HIV infection [1]. The shared use of
injection equipment can also transmit hepatitis B and C
[2-6]. The IDU population further experiences high
rates of fatal drug overdose, endocarditis, cellulitis, and
abscesses [7-10]. Injection drug users experience poor
health outcomes due to delayed access to effective treat-
ment, lower adherence to care and treatment regimens,
continuation of illicit drug use, depression and negative
life events [11-15].
Additionally, IDUs who do not enter treatment are six
times more likely to become infected with HIV than are
IDUs who enter and remain in treatment [9]. Milloy
and colleagues [15] reported that being unable to access
treatment was independently associated with recent
incarceration, daily use of heroin and borrowing used
syringes. Wood and colleagues [16] concluded that
IDUs’ inability to access treatment was independently
associated with syringe borrowing among HIV-negative
IDUs at risk for HIV infection.
Thus, there is considerable evidence indicating that
drug treatment for IDUs is effective in reducing these
harms [14,17-25] and improving users’ health outcomes
[13,14,19,26-29]. Research on the effectiveness of drug
treatment further indicates that increased length of time
in treatment is associated with lower rates of needle
sharing and HIV seropositivity [17,21,18]. Furthermore,
many programs provide access to AIDS education and
prevention programs, and HIV testing, and provide con-
tacts with health care systems to those clients already
infected with HIV [13,30]. The inclusion of AIDS educa-
tion programs within treatment protocols is associated
with increased knowledge of AIDS risks, and decreased
drug use and sexual behaviors that put IDUs at risk for
HIV infection and other STIs [21,25,26,29]. Treatment
therefore has the potential to address a broad social and
public health agenda valued in communities affected by
IDU.
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such as methadone maintenance treatment, is cost-
effective, and is a key component for supporting harm
reduction efforts among IDUs. Pollack [31] for example,
explores the cost-effectiveness of methadone maintenance
as an HIV prevention strategy. Epidemiological models
suggest that methadone treatment is cost-effective for
reducing HIV incidence at an average cost of between
$100,000 and $300,000 per infection averted. This research
also concludes that methadone maintenance is most cost-
effective in reducing HIV prevalence when treatment
reaches a large proportion of IDUs within a given commu-
nity [31]. Lastly, according to a 1998 study by Harwood
[32], the cost benefits of methadone maintenance treat-
ment show that costs to society from criminal activities
related to opioid use can run as high as four times more
than the costs for methadone treatment.
Though a number of studies have demonstrated that
drug treatment program are effective in reducing drug
use and other harm among IDUs [21,33-38], relatively
little research has been done on the extent to which
IDUs are actually reached by drug treatment programs
(i.e. drug treatment coverage). While there is no level of
coverage that universally has been agreed upon in pre-
venting HIV among IDUs [22], current levels of HIV
services for IDUs vary substantially and are inadequate
in preventing HIV transmission [23,24]. And, although
100% drug treatment coverage for IDUs should be the
ultimate goal, it may be both unrealistic and impossible
to attain, as not all IDUs want to be in treatment, and
t h o s ew i t ho p i o i dd e p e n d e n c eo f t e nh a v eah i g hr a t eo f
relapse, cycling in and out of treatment programs.
For the purposes of this study, coverage is defined as
the percentage of IDUs who are in drug treatment in a
given time period. Treatments included in our coverage
estimates are residential or ambulatory inpatient/outpa-
tient care, detoxification services and methadone main-
tenance therapy at publicly- and privately-funded
substance abuse agencies receiving public funds. These
are facilities licensed, certified, or otherwise approved by
State substance abuse agencies to provide substance
abuse treatment.
In this study we extend the scope of an earlier cross-
sectional study on treatment coverage [39] to include
longitudinal data, and we describe change in drug treat-
ment coverage for IDUs during 1993-2002 in 90 metro-
politan statistical areas ( M S A s ) .[ N O T E :T h i ss t u d y
considers data collected prior to the availability of
buprenorphine and naltrexone in the U.S.] Research on
treatment coverage can provide insight to public policy
planners, treatment providers and harm reduction acti-




We calculated treatment coverage rates using two data
series from the Substance Abuse and Mental Health
Service Administration (SAMHSA), and estimates of
IDUs from previous research [40]. Below we describe
each data series:
1) Proportion of treatment entrants who indicated
that they injected substances intravenously in each
MSA and year as reported by the Treatment Episode
Data Set (TEDS) [41];
2) Total number of drug users in drug treatment as
of October 1 of each year reported by the Uniform
Facility Data Set (UFDS) for 1993, 1995, 1996-1998
and the National Survey of Substance Abuse Treat-
ment Services (N-SSATS) for 2000 and 2002 [42];
3) Total number of IDUs in each MSA and year as
reported by Brady and colleagues [40].
We determine changes in coverage within each MSA
where treatment coverage values were regressed on
calendar year.
Unit of Analysis and Sample
We studied 90 MSAs as defined by the US Census as of
1993 [43]. MSAs are defined as a set of contiguous
counties that contain a central city of 50,000 people or
more and form a socioeconomic unit determined
according to commuting patterns and social and eco-
nomic integration within the constituent counties.
Data
We define treatment coverage as the ratio of IDUs in
treatment to IDUs in the MSA. Treatment coverage for
IDUs is estimated using TEDS and UFDS/N-SSATS.
Each of our data sets differs in counts of substance
abuse treatment clients. TEDS counts each admission in
a given year. Therefore, an individual admitted to treat-
ment twice in a calendar year is counted as two admis-
sions, which inflates annual treatment entries. In
contrast, UFDS/N-SSATS is a one day census of treat-
ment, but does not report on the route of administra-
tion. By multiplying the percent of entrants who are
IDUs (from TEDS) by the UFDS/N-SSATS census total
we can estimate the number of IDUs in treatment. The
proportion of entrants who are IDUs is only biased to
the extent that double-counting of entrants varies sys-
tematically by route of administration.
The TEDS data series identifies the number and attri-
butes of clients who enter substance abuse treatment
programs. From TEDS, we calculated the proportion of
treatment entrants who reported they injected drugs as
a mode of administration. Our second SAMHSA data
source comes from the annual census of drug treatment
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Data Set (UFDS) - but since renamed the National Sur-
vey of Substance Abuse Treatment Services (N-SSATS).
UFDS/N-SSATS data measure client characteristics and
use of privately- and publicly-funded substance abuse
treatment programs in the U.S. on October 1 for each
year. However, UFDS/N-SSATS data were unavailable
for 1992, 1994, 1999, and 2001. As a result of this lim-
ited availability, our drug treatment estimates were only
created for years where data were available. Thus, our
final coverage estimates only include data for 1993,
1995, 1996-1998, 2000, and 2002.
Calculating Number of IDUs
Because estimation of the total numbers of injectors is
discussed in detail elsewhere [40], it is described only
briefly here. Brady and colleagues first estimated the
number of IDUs in the US each year from 1992-2002
and then apportioned these estimates to MSAs using
multiplier methods. Four different types of data indicat-
ing drug injection were used to allocate national annual
totals to MSAs, creating four distinct series of estimates
of the number of injectors in each MSA. These esti-
mates rely on using (1) HIV counseling and testing data
from the Centers for Disease Control (CDC); (2) SAM-
SHA’sU F D Sa n dT E D Sd a t a ;( 3 )C D C ’s diagnoses of
IDUs with HIV/AIDS; and (4) an estimate derived from
published estimates of the number of injectors living in
each MSA in 1992 [44] and in 1998 [45]. Each series
was smoothed over time using loess regression and the
mean value of the four component estimates was taken
as the best estimate of IDUs for that MSA and year.
Brady results indicated that nationwide IDU prevalence
was relatively stable from 1992 to 2002; with a decreasing
average trend across the 96 MSAs, until 2000, after
which there was a slight increase; and individual MSAs
deviate considerably from the average trend of the 96
MSAs. IDU prevalence varied from 30 to 348 across
MSAs (mean 126.9, standard deviation 65.3, median
106.6, interquartile range 78-162) in 1992 and from 37 to
336 across MSAs (mean 110.6, standard deviation 57.7,
median 96.1, interquartile range 67-134) in 2002 [40].
In order to avoid circularity, the estimated numbers of
IDUs in the population used in this study modify the
Brady estimates so that they do not rely on data on the
numbers of IDUs in drug treatment from SAMSHA.


























Ajt = treatment coverage rate for an MSA j in year t
Bjt = number of IDUs entering drug treatment as
reported by TEDS for an MSA j in year t
Cjt = number of IDUs and NIDUs entering drug
treatment as reported by TEDS for an MSA j in
year t
Djt = number of drug users entering drug treatment
reported by UFDS/N-SSATS for an MSA j in year t
Ejt = estimated number of IDUs for an MSA j in
year t
Calculating Change in Drug Treatment Coverage Rates
In order to use all of the available data to estimate
change and test change for statistical significance within
each MSA, MSA-specific treatment coverage values
were regressed on calendar year. For each of these linear
regression models, the coefficient for year and its stan-
dard error was multiplied by nine to represent the total
model-predicted linear change in treatment coverage
from 1993 to 2002. The regression coefficient for the
effect of year within each MSA was tested for signifi-
cance using a two-tailed p < 0.05 criterion. Since our
aim here was to estimate change in each MSA sepa-




Additional file 1: Appendix 1 presents data on treatment
coverage for each MSA in 1993 and 2002 and on change
in coverage over time. Coverage overall changed little
from 1993 to 2002. Mean coverage was only 8.3% (stan-
dard deviation 4.28%; interquartile range 5.0%-11.0%) in
2002 (Table 1), a slight increase from 6.7% in 1993
(standard deviation 3.7%; interquartile range 4.0%-9.0%).
Median treatment coverage increased only from 6.0% in
1993 to 8.0% in 2002.
Linear Regression Estimates of Change Over time
The regression estimates of change also depict slow
growth in overall coverage during the study period
(mean = 1.58%; median = 1.37%; standard deviation
3.43%; interquartile range -0.57% to 3.08%).
Fifteen MSAs experienced statistically significant
increases in treatment coverage; of those, seven experi-
enced increases of less than 5% (Atlanta, GA; Cleveland,
OH; Dayton-Springfield, OH; Grand Rapids-Muskegon,
MI; Miami, FL; Rochester, NY; West Palm Beach, FL).
Seven MSAs experienced significant increases of
between 5% and 10% (Detroit, MI; El Paso, TX; Mon-
mouth-Ocean, NJ; Nassau-Suffolk, NY; New York, NY;
Newark, NJ; Wilmington-Newark, DE-MD), and one
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NY). Three MSAs exhibited a statistically significant
decrease in coverage ranging between -3.9 to -7.1
(Tacoma, WA; Fresno, CA; Honolulu, HI). Fully 80% of
MSAs (N = 72) in the study experienced no statistically
significant change in treatment coverage over time.
Discussion
The overall level of treatment coverage for IDUs in our
90 MSAs began low and remained low through the end
of the study period. Our results indicate there was a
slight increase in average drug treatment coverage from
6.7% to 8.3% across 90 MSAs from 1993 to 2002. Fifteen
MSAs experienced statistically significant increases in
treatment coverage. Of those, only eight MSAs experi-
enced increases of 5% or more (and all increases were
<11%). Three MSAs exhibited a statistically significant
decline in coverage. During this period, estimated treat-
ment coverage in 72 MSAs did not change significantly
over time.
Some of the statistically significant changes (e.g., Cle-
veland, OH; Dayton-Springfield, OH; Miami, FL) were
small in size. The fact that Cleveland and other MSAs
had significant increases (< 5%) while Jersey City and
Providence-Fall River (> 5%) did not is due to differ-
ences in the standard variation. The authors note that
several of the statistically significant increases are quite
small in magnitude, but are otherwise statistically reli-
able with regard to treatment coverage change over
time.
Although outpatient methadone maintenance has been
shown to be an effective treatment modality for opioid
dependent patients by 1997, only 7% of all treatment
facilities offered outpatient methadone treatment, repre-
senting approximately 14-15% of all clients in the treat-
ment system. Of these, 30% of outpatient methadone
maintenance facilities are private for-profit, 53% are pri-
vate non-profit, and 18% are publicly owned [46].These
figures remain unchanged in 2008, with only 8% of all
substance abuse treatment facilities offering some type
of opioid replacement therapy, either methadone or
buprenorphine [47].
The need for increased investment in drug abuse
treatment programs was underscored in the 2008
National Survey on Drug Use and Health, where 3.0% of
the total population (i.e., 7.6 million persons aged 12 or
older) were estimated to be in need of treatment for an
illicit drug use problem. Of those individuals, 1.2 million
or 0.5% of the total population received treatment –
yielding a 16% coverage rate for drug users overall. This
contrasts with only 8% for IDUs. Thus, an estimated
2.5% of the population (6.4 million) in need of treatment
for an illicit drug use problem did not receive treatment,
a figure that remains unchanged since 2002 [48].
A greater investment in treatment will likely be needed
to have a substantial impact on injection drug use and
associated harms. Investment in drug treatment expan-
sion should be viewed as sound public health policy.
Limitations
Certain limitations must be taken into account when
interpreting data from TEDS and UFDS/N-SSATS. Dur-
ing our study period, SAMSHA eliminated questions
from UFDS about the number of IDUs in treatment
programs after 1998. We therefore multiplied the pro-
portion of drug users entering treatment who inject
drugs (from TEDS) in each MSA and year by the total
number of drug users in treatment as reported by both
UFDS/N-SSATS. Second, these data sets differ in what
they count: TEDS counts each admission in a given
year, so an individual who enters drug treatment twice
or more in a year is counted as two or more indepen-
dent cases. In contrast, UFDS/N-SSATS client count
n u m b e r sa r eap o i n t - p r e v a l e n c es u r v e y –those in treat-
ment on one specific day. It gives a snap-shot of what
the substance abuse treatment system looks like on an
Table 1 Estimated drug treatment coverage rates (percent in treatment) among injection drug users in 90 large US
MSAs, 1993-2002
Mean Standard Deviation Median Interquartile Range Minimum Maximum
Treatment Coverage
1993 6.72 3.67 6.00 4.00, 9.00 1.00 16.00
1995 6.69 4.18 5.67 3.51, 9.51 0.86 20.68
1996 6.65 4.04 5.03 3.42, 9.62 0.88 18.14
1997 6.35 4.10 5.41 3.32, 9.04 0.09 20.73
1998 7.73 5.28 6.54 3.64, 11.04 0.00 26.20
2000 7.34 4.49 6.23 3.81, 9.84 0.43 23.78
2002 8.27 4.28 8.00 5.00, 11.00 1.00 21.00
Change††† 1.58 3.43 1.37 -0.57, 3.08 -9.44 10.65
NOTE: All values are percentages
††† from 1993-2002 as predicted by linear regression model
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IDUs in the ratio of admissions to those remaining in
treatment, our estimates will be biased.
Additionally, change in our estimated numbers of
IDUs in treatment in an MSA might in part result from
change in which treatment facilities in an MSA respond
to SAMSHA surveys. The survey response rate increased
from 87% in 1995 to 96% in 2002, producing an 11%
increase in reported U.S. client totals from 1993-2002.
SAMSHA attempts to obtain responses from all known
treatment facilities, but the survey is voluntary and no
adjustments for facility non-response are made. Thus,
the estimated increases in treatment coverage may par-
tially reflect changes in survey methodology.
Finally, IDUs estimates beyond 2002 are currently
being updated and were not readily available for our
coverage estimates. Thus, our data does not extend
beyond 2002. Nevertheless, there is little evidence to
suggest that the number of IDUs in MSAs and the
number of IDUs in treatment among the MSAs has sig-
nificantly changed since then.
Conclusions
The evidence in this paper clearly indicates the need to
expand drug treatment for IDUs. Coverage may be even
lower in non-metropolitan suburbs or rural areas, since
they tend to have fewer available healthcare services.
Injection drug use poses serious public health chal-
lenges with respect to public policy. Low treatment cov-
erage for IDUs may produce a high cost to society in
terms of the spread of HIV, hepatitis B and C and other
infectious diseases among injectors, their partners, and
the broader community. Drug treatment such as metha-
done maintenance therapy can address a broad social
and public health agenda valued in communities affected
by IDU. The persistent low drug treatment coverage for
IDUs represents a failure of the U.S. healthcare system to
prevent avoidable harms and unnecessary deaths.
More research is needed to address what policy and
structural changes affect variations and changes in treat-
ment coverage - and, in particular, what combinations
of factors lead to increases in treatment coverage. Such
research can help public policy planners, treatment pro-
viders and harm reduction activists understand the bar-
riers to expanded drug treatment for IDUs.
Coverage rates in U.S. MSAs during the study period are
far below international standards. Some European Union
(EU) countries maintain coverage levels of 60% or higher
[49]. The World Health Organization [22] has set targets
for universal access to HIV prevention, treatment and care
for IDUs. Targets for treatment coverage for IDUs acces-
sing opioid substitution therapy define “ <20%” as “low”
and “>4 0 % ” as “high [22].” Switzerland, where opioid sub-
stitution therapy is freely available, has attained treatment
coverage levels of up to 70% over time [50]. Treatment
coverage rates in the EU and other countries (e.g. Austra-
lia, 50%) are higher in comparison with U.S. Clearly, more
funding for drug treatment services for IDUs is needed
from U.S. government sources to increase the overall level
of treatment coverage to a level comparable to what the
EU and other countries attain. Reducing the harm asso-
ciated with injection drug use and making drug treatment
accessible and a high public health priority is sound public
health and government policy.
Additional material
Additional file 1: Appendix 1. Distribution and Change in Estimated
Drug Treatment Coverage Rates among Injection Drug Users (IDUs)
1993-2002.
Acknowledgements
This project was supported by the National Institute of Drug Abuse (R01
DA13336; Community Vulnerability and Response to IDU-Related HIV). We
kindly acknowledge from the Substance Abuse and Mental Health Services
Administration, Dr. Cathie E. Alderks; Deborah Trunzo and Gerri Scott-
Pinkney for their assistance. The authors also thank Mr. Lucas Wiessing from
the European Monitoring Centre for Drugs and Drug Addiction in Lisbon,
Portugal for his thoughtful discussion and knowledge regarding drug
treatment coverage in the European Union and elsewhere.
Authors’ contributions
BT was responsible for data acquisition, analysis, and interpretation; and the
writing of the article. CMC contributed to the analysis and interpretation of
the data; and the writing of the article. SRF contributed to the conception
and design of the analysis and the writing. ERP contributed to the writing of
the article. SC contributed to data acquisition. BT, CMC, SRF, ERP, and SC
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 6 April 2010 Accepted: 21 September 2010
Published: 21 September 2010
References
1. Centers for Disease Control and Prevention. US Department of Health and
Human Services: HIV/AIDS Surveillance Report. 2007, 19, Accessed March
16, 2010.
2. Burt RD, Hagan H, Garfein RS, Sabin K, Weinbaum C, Thiede H: Trends in
hepatitis B virus, hepatitis C virus, and human immunodeficiency virus
prevalence, risk behaviors, and preventive measures among Seattle
injection drug users aged 18-30 years, 1994-2004. Journal of Urban Health
2007, 84:436-454.
3. Vassilev ZP, Hagan H, Lyubenova A, Tomov N, Vasilev G, Krasteva D, Des
Jarlais DC: Needle exchange use, sexual risk behaviour, and the
prevalence of HIV, hepatitis B virus, and hepatitis C virus infections
among Bulgarian injection drug users. International Journal of STD and
AIDS 2006, 17:621-626.
4. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD,
Cheever LW, Cargill VA: Overcoming barriers to prevention, care, and
treatment of hepatitis C in illicit drug users: A review. Clinical Infectious
Diseases 2005, 40:S5, S276-85.
5. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C: Meta-regression
of hepatitis C virus infection in relation to time since onset of illicit drug
injection: The influence of time and place. American Journal of
Epidemiology 2008, 168:1099-1109.
Tempalski et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:23
http://www.substanceabusepolicy.com/content/5/1/23
Page 5 of 76. Vlahov D, Des Jarlais DC, Goosby E, Hollinger PC, Lurie PG, Shriver MD,
Strathdee SA: Needle exchange programs for the prevention of human
immuno-deficiency virus infection: Epidemiology and policy. American
Journal of Epidemiology 2001, 154:S70-S77.
7. Cooper H, Brady J, Ciccarone D, Tempalski B, Gostnell K, Friedman SR:
Suboxone and Rising Hospitalizations for Infective Endocarditis among
Injection Drug Users in the USA: No Evidence of a Causal Link. Clinical
Infectious Diseases 2008, 46:955-956.
8. Spijkerman IJ, van Ameijden EJ, Mientjes GH, Coutinho RA, van den Hoek A:
Human immunodeficiency virus infection and other risk factors for skin
abscesses and endocarditis among injection drug users. Journal of
Clinical Epidemiology 1996, 49:1149-1154.
9. Centers for Disease Control and Prevention: Unintentional opiate overdose
deaths—King County, Washington, 1990–1999. Morbidity and Mortality
Weekly Report 2000, 48:636-40.
10. Morgan O, Griffiths C, Hickman M: Association between availability of
heroin and methadone and fatal poisoning in England and Wales 1993-
2004. International Journal of Epidemiology 2006, 35:1579-1585.
11. Lert F, Kazatchkine MD: Antiretroviral HIV treatment and care for injecting
drug users: An evidence-based overview. International Journal of Drug
Policy 2007, 18:255-261.
12. Flanigan TP, Mitty JA, Macalino GE: Directly Observed Therapy and Other
Community-Based Efforts to Improve Adherence to HAART. Clinical
Infectious Diseases 2004, 38:S5, S373-436.
13. Spire B, Lucas GM, Carrieri MP: Adherence to HIV treatment among IDUs
and the role of opioid substitution treatment (OST). International Journal
of Drug Policy 2007, 18:262-70.
14. Fischer B, Oviedo-Joekes E, Blanken P, Haasen C, Rehm J, Schechter MT,
Strang J, Van den Brink W: Heroin-assisted Treatment (HAT) a Decade
Later: A Brief Update on Science and Politics. Journal of Urban Health
2007, 84:552-562.
15. Milloy MJ, Kerr T, Zhang R, Tyndall M, Montaner J, Wood E: Inability to
access addiction treatment and risk of HIV infection among injection
drug users recruited from a supervised injection facility. Journal of Public
Health 2009, Accessed June 18, 2010.
16. Wood E, Spittal P, Li K, Kerr T, Miller CL, Hogg RS, Montaner J,
Schechter MT: Inability to Access Addiction Treatment and Risk of HIV
Infection Among Injection Drug Users. Journal of Acquired Immune
Deficiency Syndromes 2004, 36:750-754.
17. Friedman SR, Jose B, Deren S, Des Jarlais DC, Neaigus A, National AIDS
Research Consortium: Risk factors for HIV seroconversion among out-of-
treatment drug injectors in high- and low-seroprevalence cities.
American Journal of Epidemiology 1995, 142:864-874.
18. Metzger D: Drug abuse treatment as AIDS prevention. Public Health
Reports 1998, 113:97-106.
19. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE:
Buprenorphine Use: The International Experience. Clinical Infectious
Diseases 2006, 43:S4, S197-S215.
20. Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy
versus no opioid replacement therapy for opioid dependence Cochrane
Review. The Cochrane Library 2002, 3.
21. Sorensen JL, Copeland AL: Drug abuse treatment as an HIV prevention
strategy: a review. Drug and Alcohol Dependence 2000, 59:17-31.
22. World Health Organization, United Nations Office on Drugs and Crime,
Joint United Nations Programme on HIV/AIDS: Technical guide for
countries to set targets for universal access to HIV prevention,
treatment and care for injecting drug users. [http://www.unodc.org/
documents/hiv-aids/idu_target_setting_guide.pdf], Accessed March 1,
2010.
23. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP,
Myers B, Ambekar A, Strathdee SA: HIV prevention, treatment, and care
services for people who inject drugs: a systematic review of global,
regional, and national coverage. Lancet 2010, 375:1014-1028.
24. National Institute on Drug Abuse: Global Coverage of HIV Services for
Injecting Drug Users Inadequate to Prevent HIV Transmission.
NEWSSCAN: NIDA Addiction Research News 2010, Special.
25. Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D, Hogg RS,
Montaner JS, Wood E: Methadone maintenance therapy promotes
initiation of antiretroviral therapy among injection drug users. Addiction
2010, 105:907-913.
26. van Beek I: Case study: Accessible primary health care–A foundation to
improve health outcomes for people who inject drugs. International
Journal of Drug Policy 2007, 18:329-332.
27. Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L: The
potential role of buprenorphine in the treatment of opioid dependence
in HIV-infected individuals and in HIV infection prevention. Clinical
Infectious Diseases 2006, 43:S4, S178-83.
28. Camacho LM, Bartholomew NG, Joe GW, Cloud MA, Simpson DD: Gender,
cocaine and during-treatment HIV risk reduction among injection opioid
users in methadone maintenance. Drug and Alcohol Dependence 1996,
41:1-7.
29. Longshore D, Hsieh S: Drug abuse treatment and risky sex: evidence for
a cumulative treatment effect? American Journal of Drug & Alcohol Abuse
1998, 24:439-451.
30. Holtgrave DR, Qualls NL, Curran JW, Valdiserri RO, Guinan ME, Parra WC: An
overview of the effectiveness and efficiency of HIV prevention
programs. Public Health Reports 1995, 110:134-146.
31. Pollack H: Cost-effectiveness of methadone treatment as HIV prevention.
National HIV Prevention Conference. (Abstract No. 598) Atlanta, Ga 1999.
32. Harwood H, Fountain D, Livermore G: The Economic Costs of Alcohol and
Drug Abuse in the United States 1992. National Institutes on Drug Abuse
Rockville, MD 1998.
33. Rhodes T, Kimber J, Small W, Fitzgerald J, Kerr T, Hickman M, Holloway G:
Public injecting and the need for ‘safer environment interventions’ in
the reduction of drug-related harm. Addition 2006, 101:1384-1393.
34. World Health Organization: Effectiveness of drug dependence treatment
in preventing HIV among injecting drug users: Evidence for action
technical paper and policy brief. 2005, Accessed March 1, 2010.
35. Schumacher JE, Mennemeyer ST, Milby JB, Wallace D, Nolan K: Costs and
Effectiveness of Substance Abuse Treatments for Homeless Persons. The
Journal of Mental Health Policy and Economics 2002, 5:33-42.
36. Sindelar JL, Fiellin D: Innovations in Treatment for Drug Abuse. Annual
Review of Public Health 2001, 22:249-72.
37. Simpson DD, Flynn PM: Drug Abuse Treatment Outcome Studies
(DATOS): A national evaluation of treatment effectiveness. In
Encyclopedia of Substance Abuse Prevention, Treatment, and Recovery. Edited
by: Fisher G, Roget N. Thousand Oaks, CA: Sage Publishing; 2008:303-307.
38. Barnett PG, Hui SS: The cost-effectiveness of methadone maintenance. Mt
Sinai Journal of Medicine 2000, 67:365-374.
39. Friedman SR, Tempalski B, Brady J, Friedman JJ, Cooper H, Flom PL,
McGrath MM, Gostnell K, Des Jarlais DC: Predictors of the degree of drug
treatment coverage for injection drug users in 94 metropolitan areas in
the United States. International Journal on Drug Policy 2007, 18:475-485.
40. Brady JE, Friedman SR, Cooper HLF, Flom PL, Tempalski B, Gostnell K:
Estimating the prevalence of injection drug users in the US and in large
US metropolitan areas from 1992-2002. Journal of Urban Health 2008,
85:323-351.
41. Department of Health and Human Services, Office of Applied Studies:
Treatment Episode Data Set (TEDS) 1992-2002: [United States]
[Computer file], ver. 2
nd ICPSR04431 version. Ann Arbor, MI: Synectics for
Management Decisions, Incorporated. Inter-university Consortium for Political
and Social Research 2006.
42. Department of Health and Human Services SAMHSA, Office of Applied Studies:
National Survey of Substance Abuse Treatment Services (N-SSATS), 2000,
2002: [United States] [Computer file], ver. 3
rd ICPSR version. Ann Arbor, MI:
Synectics for Management Decisions, Incorporated. Inter-university Consortium for
Political and Social Research 2006.
43. Office of Management and Budget: Standards for defining metropolitan
and micropolitan statistical areas. Federal Register 2000, 65:82228-82238.
44. Holmberg S: The estimated prevalence and incidence of HIV in 96 large
U.S. metropolitan areas. American Journal of Public Health 1996, 86:642-654.
45. Friedman SR, Tempalski B, Cooper H, Perlis T, Keem M, Friedman R,
Flom PL: Estimating numbers of injecting drug users in metropolitan
areas for structural analyses of community vulnerability and for
assessing relative degrees of service provision for injecting drug users.
Journal of Urban Health 2004, 81:377-400.
46. Substance Abuse and Mental Health Services Administration: Results from
the 2002 National Survey on Drug Use and Health: National Findings.
Office of Applied Studies. (DHHS Publication No. SMA 03-3836, NHSDA Series
H-22) Rockville, MD 2003.
Tempalski et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:23
http://www.substanceabusepolicy.com/content/5/1/23
Page 6 of 747. Substance Abuse and Mental Health Services Administration: The N-SSATS
Report: Overview of Opioid Treatment Programs within the United
States: 2008. Office of Applied Studies Rockville, MD 2010.
48. Substance Abuse and Mental Health Services Administration SAMHSA:
Results from the 2008 National Survey on Drug Use and Health:
National Findings. Office of Applied Studies, NSDUH Series H-36, HHS
Publication No. SMA 09-4434 Rockville, MD 2009.
49. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA):
2009 Annual Report on the State of the Drugs Problem in the European
Union. Lisbon 2009, Accessed March 2, 2010.
50. Nordt C, Stohler R: Incidence of heroin use in Zurich, Switzerland: A
treatment case registers analysis. Lancet 2006, 367:1830-34.
doi:10.1186/1747-597X-5-23
Cite this article as: Tempalski et al.: Persistence of low drug treatment
coverage for injection drug users in large US metropolitan areas. Substance
Abuse Treatment, Prevention, and Policy 2010 5:23.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tempalski et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:23
http://www.substanceabusepolicy.com/content/5/1/23
Page 7 of 7